A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Idecabtagene vicleucel (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms KarMMa
- Sponsors Celgene Corporation
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Aug 2023 Results of Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in this study , published in the Advances in Therapy
- 06 Jun 2023 Results from KarMMa (NCT03361748) and KarMMa-2 (NCT03601078) studies, assessing baseline characteristics identifying patients with multiple myeloma treated with idecabtagene vicleucel who are at risk for severe/refractory inflammatory adverse events, presented at the 59th Annual Meeting of the American Society of Clinical Oncology